Aliskiren Improves Left Ventricular Dysfunction and Reduces Cardiac Dilation in Syrian Cardiomyopathic Hamsters

摘要: OBJECTIVE Chronic activation of the renin-angiotensin-aldosterone system is a major contributing factor to pathogenesis and progression cardiovascular renal diseases. METHODS To evaluate role blockade with aliskiren, direct renin inhibitor, in development dilated cardiomyopathy Syrian cardiomyopathic hamster (SCH) model, we treated 1-month-old SCH aliskiren (10 mg·kg·d) over 4-month period. For comparative purposes, also evaluated effects angiotensin receptor blocker valsartan combination both drugs. Age-matched golden hamsters were used as controls. Left ventricular end-diastolic volume end-systolic volume, ejection fraction, diastolic function determined by echocardiography. Systolic blood pressure (SBP) was measured left femoral artery sphygmomanometry. RESULTS Results indicate that at 2 months age, SBP higher than controls, administration for 1 month valsartan, or these drugs normalized similar extent. In 5-month-old SCH, improved fraction (from 48.6% ± 5.8% 69.4% 3.2%, n = 5, P < 0.05), 0.28 0.06 0.10 0.01 mL/100 g body weight), 0.61 0.05 0.34 0.02 (E:A ratio increases from 0.93 0.13 1.70 0.03, 0.05). Similar results observed valsartan. CONCLUSIONS Our this animal effective drugs, improving preventing cardiomyopathy. These findings suggest may be monotherapy heart failure management. Clinical studies, however, are needed assess effectiveness drug patients failure.